Common treatment endometriosis linked to ovarian cancer, say University of Pittsburgh researchers

March 17, 2002

PITTSBURGH, March 17 - A commonly prescribed medication for treating endometriosis appears to elevate the risk of ovarian cancer, according to findings presented by a University of Pittsburgh Graduate School of Public Health (GSPH) researcher at the 33rd annual meeting of the Society of Gynecologic Oncologists in Miami.

In the study, women taking danazol, a synthetic version of the male hormone androgen, were nearly three times more likely to develop ovarian cancer than were women taking leuprolide, an anti-androgenic, gonadotropin-releasing hormone agonist. Both drugs are used to treat endometriosis, a painful disease in which pieces of uterine tissue migrate to other parts of the body.

"Our previous studies have found that women with endometriosis are already at a 50-percent increased risk for ovarian cancer, and treating them with danazol appears to further increase their risk. This new result, even though it is preliminary, may factor into the equation when clinicians and their patients with endometriosis are deciding on the best treatment," said presenter Roberta B. Ness, M.D., M.P.H., associate professor of epidemiology at the GSPH and director of the school's Epidemiology of Women's Health Program.

The study analyzed pooled data from two case-control studies that examined the relationships among endometriosis, endometriosis treatments and ovarian cancer. Among women with endometriosis, 17 took danazol and 15 took leuprolide. Analysis showed that the study participants who took danazol were 2.7 times more likely to have ovarian cancer than were other women with endometriosis who did not take danazol. Women taking leuprolide had no significant elevation in risk.

"While the number of women studied is small, the results are telling, and they warrant further studies on a larger scale," said the study's principal investigator, Carrie Cottreau, Ph.D., assistant professor of obstetrics and gynecology, University of Pittsburgh School of Medicine.

Additional research studies are planned at the University of Pittsburgh to further investigate the link between androgens and ovarian cancer.

Earlier this year, Dr. Ness and colleagues published results of a study showing that there is no association between fertility drugs and ovarian cancer. However, the study showed that the risk of ovarian cancer is 50 percent higher in women with endometriosis than it is for women without endometriosis.
Established in 1948, the University of Pittsburgh Graduate School of Public Health is considered a leader in the field of women's health research and is world-renowned for contributions that have influenced public health practices and medical care for millions of people. It is the only fully accredited school of public health in the Commonwealth of Pennsylvania and is one of the top-ranked schools of public health in the United States. It is one of eight schools across the country to be designated a Public Health Training Center by the U.S. Department of Health and Human Services. For more information, access the school's Web site at

Kathryn Duda
Michele Baum
PHONE: 412-624-2607
FAX: 412-624-3184
PRESS ROOM: 786-276-1352

University of Pittsburgh Medical Center

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to